Delving into the Latest Updates on G.ST Antivirals GmbH with Synapse

A Randomized, Double-blind, Placebo-controlled Phase 2 Study Using the Rhinovirus Challenge Model to Investigate the Efficacy and Safety of 2-Deoxy-D-Glucose as Pre-exposure Prophylaxis

2-DG-02 is a randomized, placebo-controlled, double-blind Phase 2 study to investigate the efficacy and safety of 2-Deoxy-D-Glucose as a pre-exposure prophylaxis using the rhinovirus challenge model in healthy study participants.

开始日期2024-04-02

申办/合作机构

G.ST Antivirals GmbH初创企业

CTIS2023-509311-91-01 / Not yet recruiting

A randomized, double-blind, placebo-controlled Phase 2 study using the rhinovirus challenge model to investigate the efficacy and safety of 2-Deoxy-D-glucose as pre-exposure prophylaxis. - 2-DG-02

开始日期2024-02-26

申办/合作机构

G.ST Antivirals GmbH初创企业

NCT05314933 / Completed临床1期

A Single/Multiple Ascending Dose Phase 1 Study Of The Safety, Tolerability, And Pharmacokinetics Of Intranasal 2-Deoxy-D-Glucose In Normal Healthy Volunteers

2-DG-01 is a randomized, double-blind, placebo-controlled, single and multiple ascending dose phase 1 study assessing safety, tolerability and pharmacokinetics of 2-DG in normal healthy volunteers (NHV). The safety and pharmacokinetics of 2-DG are assessed after single or multiple intranasal administrations.

开始日期2022-03-03

申办/合作机构

G.ST Antivirals GmbH初创企业

100 项与 G.ST Antivirals GmbH 相关的临床结果

登录后查看更多信息

0 项与 G.ST Antivirals GmbH 相关的专利（医药）

登录后查看更多信息

2

项与 G.ST Antivirals GmbH 相关的文献（医药）

2022-12-01·Journal of Virus Eradication

Host-directed therapy with 2-deoxy-D-glucose inhibits human rhinoviruses, endemic coronaviruses, and SARS-CoV-2

Article

作者: Kreil, Thomas R ; Gösler, Irene ; Gualdoni, Guido A ; Chou, Scharon ; Stoeva, Delyana ; Gorki, Anna-Dorothea ; Stöckl, Johannes ; Karbiener, Michael ; Blaas, Dieter ; Contreras, Ximena ; Kovtunyk, Vitalii ; Adonyi, Adam ; Wali, Laxmikant

Rhinoviruses (RVs) and coronaviruses (CoVs) upregulate host cell metabolic pathways such as glycolysis to meet their bioenergetic demands for rapid multiplication. Using the glycolysis inhibitor 2-deoxy-d-glucose (2-DG), we assessed the dose-dependent inhibition of viral replication of minor- and major-receptor group RVs in epithelial cells. 2-DG disrupted RV infection cycle by inhibiting template negative-strand as well as genomic positive-strand RNA synthesis, resulting in less progeny virus and RV-mediated cell death. Assessment of 2-DG's intracellular kinetics revealed that after a short-exposure to 2-DG, the active intermediate, 2-DG6P, is stored intracellularly for several hours. Finally, we confirmed the antiviral effect of 2-DG on pandemic SARS-CoV-2 and showed for the first time that it also reduces replication of endemic human coronaviruses. These results provide further evidence that 2-DG could be used as a broad-spectrum antiviral.

bioRxiv

Host-directed therapy with 2-Deoxy-D-glucose inhibits human rhinoviruses, endemic coronaviruses, and SARS-CoV-2

作者: Gualdoni, Guido A. ; Blaas, Dieter ; Chou, Scharon ; Stoeva, Delyana ; Gorki, Anna-Dorothea ; Kreil, Thomas R. ; Karbiener, Michael ; Contreras, Ximena ; Stoeckl, Johannes ; Goesler, Irene ; Kovtunyk, Vitalii ; Adonyi, Adam ; Wali, Laxmikant

Rhinoviruses (RVs) and coronaviruses (CoVs) upregulate host cell metabolic pathways including glycolysis to meet their bioenergetic demands for rapid multiplication.Using the glycolysis inhibitor 2-deoxy-D-glucose (2-DG), we confirm the dose-dependent inhibition of minor- and major-receptor group RV replication.We demonstrate that 2-DG suppresses viral pos.- as well as neg.-strand RNA synthesis, resulting in lower amounts of progeny virus and RV-mediated cell death.In tissue culture with physiol. glucose levels, 2-DG has a pronounced antiviral effect.Further, assessment of 2-DG's intracellular kinetics revealed that the active intermediate, 2-DG6P, is stored intracellularly for several hours.Our concurrent study of 2-DG's impact on pandemic SARS-CoV-2 and endemic HCoVs demonstrated a significant reduction in viral load.Collectively, these results suggest 2-DG to be a broad-spectrum antiviral.

100 项与 G.ST Antivirals GmbH 相关的药物交易

登录后查看更多信息

100 项与 G.ST Antivirals GmbH 相关的转化医学

登录后查看更多信息